• Users Online: 203
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 106  |  Issue : 3  |  Page : 134-137

Comparison of the effects of multiple intravitreal bevacizumab injections and single triamcinolone acetonide injection in diabetic macular edema


Mansoura Ophthalmic Center, Mansoura University, Mansoura, Egypt

Correspondence Address:
Mohammed M Elwan
Mansoura Ophthalmic Center, Mansoura University, Mansoura
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2090-0686.127355

Rights and Permissions

Purpose The aim of this study was to compare the effects of a single intravitreal injection of triamcinolone acetonide versus three consecutive monthly intravitreal injections of bevacizumab for the treatment of diabetic macular edema. Patients and methods In this prospective, randomized study, patients were divided into two groups: 15 eyes that were treated with three consecutive monthly intravitreal injections of 1.25 mg bevacizumab (bevacizumab group) and 15 eyes treated with single intravitreal injections of 4 mg triamcinolone acetonide (triamcinolone group). Changes in the best-corrected visual acuity (BCVA), intraocular pressure, and optical coherence tomography measurements were evaluated in both groups. Follow-up visits up to 3 months from baseline were reported. Results The bevacizumab group showed a significant decrease in the median central foveal thickness from 236 μm ± 91.5 to 221 μm ± 43.5 after 3 months (P < 0.05). The triamcinolone group also showed a significant reduction in central foveal thickness from 339 μm ± 130.5 to 273 μm ± 84.5 (P < 0.05). The bevacizumab group showed an increase in the BCVA from a median of 0.8 ± 0.45 logMAR to a median of 0.48 ± 0.3 logMAR after 3 months (P < 0.05). The triamcinolone group also showed an increase in BCVA from a median of 0.7 ± 0.18 logMAR to a median of 0.3 ± 0.41 logMAR (P < 0.05). Statistical analysis showed no significant difference between both groups at 3 months. Conclusion A single intravitreal injection of triamcinolone acetonide is as effective as three consecutive monthly intravitreal injections of bevacizumab for the treatment of diabetic macular edema.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed759    
    Printed21    
    Emailed0    
    PDF Downloaded104    
    Comments [Add]    

Recommend this journal